Reproducibility over 5 years of measurements of 6-sulphatoxymelatonin in urine samples from postmenopausal women.

To assess the appropriateness of a single measurement of urinary 6-sulfatoxymelatonin (aMT6S) as a marker for long-term exposure to endogenous melatonin in epidemiological studies, we examined the reproducibility of aMT6S in first morning urine voids collected from 40 postmenopausal women. Urine specimens were collected on three different occasions, and the mean time between the first and the third urine sample was 5.1 years. Urinary aMT6S levels were measured by radioimmunoassay and adjusted for creatinine. The intraclass correlation for aMT6S adjusted for creatinine was 0.56 (95% confidence interval, 0.39-0.73). The classification of aMT6S concentrations in first morning voids from postmenopausal women appears to be sufficiently reproducible to justify its use as a marker for long-term exposure to melatonin in epidemiological studies.

[1]  R. Kaaks,et al.  Reproducibility over time of measurements of androgens, estrogens and hydroxy estrogens in urine samples from post-menopausal women , 2002, European Journal of Epidemiology.

[2]  W T Kaune,et al.  Residential magnetic fields, light-at-night, and nocturnal urinary 6-sulfatoxymelatonin concentration in women. , 2001, American journal of epidemiology.

[3]  M. Bourdages,et al.  Effects of electric and magnetic fields from high-power lines on female urinary excretion of 6-sulfatoxymelatonin. , 2001, American journal of epidemiology.

[4]  W. Kaune,et al.  Alcohol Consumption and Urinary Concentration of 6-Sulfatoxymelatonin in Healthy Women , 2000, Epidemiology.

[5]  Leeka Kheifets,et al.  Morning urinary assessment of nocturnal melatonin secretion in older women , 2000, Journal of pineal research.

[6]  R Kavet,et al.  Prediction of nocturnal plasma melatonin from morning urinary measures , 1998, Journal of pineal research.

[7]  G Peiker,et al.  Nocturnal urinary 6‐sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age‐matched controls and shows negative correlation with tumor‐size , 1997, Journal of pineal research.

[8]  A. Brzezinski.  Melatonin in humans. , 1997, The New England journal of medicine.

[9]  M. Dowsett,et al.  A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. , 1997, British Journal of Cancer.

[10]  J. Manson,et al.  Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  Re Waller,et al.  Principles of Exposure Measurement in Epidemiology , 1994 .

[12]  L. Kuller,et al.  Reliability and interrelations among serum sex hormones in postmenopausal women. , 1991, American journal of epidemiology.

[13]  J. Arendt,et al.  Radioimmunoassay for 6-Sulphatoxymelatonin in Urine Using an Iodinated Tracer , 1988, Annals of clinical biochemistry.

[14]  J. Arendt,et al.  Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. , 1985, The Journal of clinical endocrinology and metabolism.

[15]  E. A. Baanders-van Halewijn,et al.  The DOM project for the early detection of breast cancer, Utrecht, The Netherlands. , 1984, Journal of chronic diseases.